Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK to receive upfront payment of approximately EUR301 million and milestone payments for a total consideration of up to EUR955 million
-
Global Fund Replenishment - 2019 media statement
The Global Fund, world's largest financier of 3 of the deadliest diseases worldwide, AIDS, TB, and malaria, has helped save 27 million lives
-
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability
-
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
-
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV
Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.
-
Nucala significantly reduces exacerbations in first global prospective real-world study of a biologic in severe eosinophilic asthma
Results from interim analysis of REALITI-A study presented at ERS conference
-
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the study population compared to placebo.
-
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
-
Real-world effectiveness evidence among GSK data presented at ERS 2019
GlaxoSmithKline will for the first time share data on the effectiveness of mepolizumab in severe eosinophilic asthma patients
-
GSK receives positive CHMP opinion for intravenous Benlysta in children with lupus aged five years and above
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion
-
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
The US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old.
-
GSK to present data from its innovative oncology portfolio at ESMO Congress 2019
GSK announced that data from its growing oncology pipeline will be presented at the European Society for Medical Oncology Congress.
-
GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Belantamab mafodotin (GSK2857916) on track for regulatory submission by the end of 2019
-
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
ATLAS-2M study met its primary endpoint.
-
GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease
GSK announced, submission of JNDA for daprodustat, an oral HIF-PHI, for the treatment of renal anaemia due to CKD.
-
GSK announces leadership changes in the US
Jack Bailey, President US Pharmaceuticals has decided to step down from his role at the end of the year, succeeded by Maya Martinez-Davis.
-
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
-
Nucala receives EU approval for self-administration by patients with severe eosinophilic asthma
96% of patients in studies preferred self-administration at home over being treated in clinic
-
GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture
GSK today announced that it has completed its transaction with Pfizer to combine their consumer healthcare businesses into a Joint Venture.
-
Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements
Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe
